NHS warns serious virus 'rampant in Australia' coming to UK
The UK should brace for a surge in a potentially serious virus following a record number of cases in Australia, health experts have said.
NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England.
And following a surge in cases number of respiratory syncytial virus (RSV) cases in Australia, officials have said that cases have been steadily increasing in England since the start of 2025.
NHS England has urged pregnant women to get the vaccine which protects against RSV in order to protect their newborn babies.
It said that the virus is a leading cause of death among babies and the main cause of hospital admissions for children.
Kate Brintworth, chief midwifery officer for NHS England, said: 'While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation.
'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.'
Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery.
Older adults aged 75-79 are also eligible for the jab and NHS England will start inviting people to come forward in the next few weeks.
RSV is a common cause of coughs and colds.
But some people have a high risk of getting seriously ill from the virus including babies and adults over the age of 75.
In babies, RSV is a common cause of a type of chest infection called bronchiolitis.
Last week, the UK Health Security Agency published data showing the efficacy of the vaccine.
It said that the jab for pregnant women can prevent 72% of hospital admissions for their babies.
And the vaccine is 82% effective at preventing hospital admissions for RSV among older adults, UKHSA said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
3 hours ago
- The Guardian
OpenAI stops ChatGPT from telling people to break up with partners
ChatGPT will not tell people to break up with their partner and will encourage users to take breaks from long chatbot sessions, under new changes to the artificial intelligence tool. OpenAI, ChatGPT's developer, said the chatbot would stop giving definitive answers to personal challenges and would instead help people to mull over problems such as potential breakups. 'When you ask something like: 'Should I break up with my boyfriend?' ChatGPT shouldn't give you an answer. It should help you think it through – asking questions, weighing pros and cons,' said OpenAI. The US company said new ChatGPT behaviour for dealing with 'high-stakes personal decisions' would be rolled out soon. OpenAI admitted this year that an update to ChatGPT had made the groundbreaking chatbot too agreeable and altered its tone. In one reported interaction before the change, ChatGPT congratulated a user for 'standing up for yourself' when they claimed they had stopped taking their medication and left their family – who the user had thought were responsible for radio signals emanating from the walls. In the blog post, OpenAI admitted that there had been instances where its advanced 4o model had not recognised signs of delusion or emotional dependency – amid concerns that chatbots are worsening people's mental health crises. The company said it was developing tools to detect signs of mental or emotional distress so ChatGPT can direct people to 'evidence-based' resources for help. A recent study by NHS doctors in the UK warned that AI programs could amplify delusional or grandiose content in users vulnerable to psychosis. The study, which has not been peer reviewed, said the programs' behaviour could be because the models were designed to 'maximise engagement and affirmation'. The study added that even if some individuals benefited from AI interactions, there was a concern the tools could 'blur reality boundaries and disrupt self-regulation'. OpenAI added that from this week it would send 'gentle reminders' to take a screen break to users engaging in long chatbot sessions, similar to screen-time features deployed by social media companies. OpenAI also said it had convened an advisory group of experts in mental health, youth development and human-computer-interaction to guide its approach. The company has worked with more than 90 doctors, including psychiatrists and paediatricians, to build frameworks for evaluating 'complex, multi-turn' chatbot conversations. 'We hold ourselves to one test: if someone we love turned to ChatGPT for support, would we feel reassured? Getting to an unequivocal 'yes' is our work,' said the blog post. The ChatGPT alterations were announced amid speculation that a more powerful version of the chatbot is imminent. On Sunday Sam Altman, OpenAI's chief executive, shared a screenshot of what appeared to be the company's latest AI model, GPT-5.
South Wales Argus
3 hours ago
- South Wales Argus
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
South Wales Guardian
4 hours ago
- South Wales Guardian
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
